Market Overview

UPDATE: Piper Jaffray Upgrades Insulet Corporation to Overweight on Next Generation Approval

Related PODD
Benzinga's Top Upgrades, Downgrades For April 20, 2018
Benzinga's Top Upgrades, Downgrades For April 4, 2018

Piper Jaffray raised its rating on Insulet Corporatio (NASDAQ: PODD) from Neutral to Overweight and increased its price target from $21 to $27.

Piper Jaffray commented, "We are raising our rating from Neutral to Overweight, following PODD's FDA 510(k) clearance for its next generation OmniPod. Our Neutral rating since launching coverage in March was predicated on FDA delays and difficulties in transitioning to the new pump. Although the conversion of PODD's customer base still comes with challenges, we believe delays in approval have provided ample time for planning the conversion. The lower cost, slimmer profiled 2nd generation insulin pump could unlock 10+ points of gross margin expansion over time within the US business, with a likely GM inflection point in Q3-13 once the majority of US customers are on the new system."

Insulet Corporation closed at $21.72 on Thursday.

Latest Ratings for PODD

May 2018BMO CapitalMaintainsOutperformOutperform
Apr 2018BerenbergInitiates Coverage OnBuy
Apr 2018GuggenheimInitiates Coverage OnBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (PODD)

View Comments and Join the Discussion!